HK Stock Market Move | SICC Co., Ltd. (02631) rose by over 7%, with wide prospects for the application of silicon carbide. Institutions are optimistic about the company's long-term growth potential.
Tianyue Group (02631) surged over 7%, as of the time of writing, up 7.34% to HK$58.5, with a turnover of HK$69.0121 million.
SICC Co., Ltd. (02631) rose more than 7%, as of the time of this article, it had risen by 7.34% to HK$58.5, with a trading volume of HK$69.0121 million.
On the news front, according to CCTV Finance reports, journalists have found that many transformer factories in Guangdong and Jiangsu provinces in China are operating at full capacity, with some business orders for data centers scheduled until 2027. In response to the challenge of high proportion of new energy access, in Hebei, the exploration and application of full silicon carbide power electronic transformers technology is being carried out to reduce energy loss and improve the efficiency of new energy utilization.
Guosheng's recent research report pointed out that SiC, as a key electronic power device for SST, is expected to provide new growth momentum for it.
Zheshang previously pointed out that SICC Co., Ltd. is actively expanding the application of silicon carbide in emerging fields, opening up long-term growth space. AR glasses: Silicon carbide material is expected to become the ideal material for the next generation of AR glasses waveguide lenses due to its high refractive index and lightweight advantages, achieving better display effects. AIDC: With the explosion of AI computing power demand, the issue of data center energy consumption is becoming more prominent. Silicon carbide power devices can significantly improve server power efficiency, and with giants like Nvidia driving the trend of data centers evolving towards 800V high-voltage architecture, silicon carbide is expected to become a key material.
Related Articles

HK Stock Market Move | ZYLOXTB (02190) rose nearly 7% during trading, with strong sales growth in core products. The company expects annual net profit to increase nearly 1.4 times year-on-year.

Hubei Biocause Heilen Pharmaceutical (301211.SZ): approval of market application for gefitinib hydrochloride chemical raw material drug.

Palantir (PLTR.US) FY25 Q4 earnings call: Remaining contract value grew 105% year-on-year to reach $11.2 billion.
HK Stock Market Move | ZYLOXTB (02190) rose nearly 7% during trading, with strong sales growth in core products. The company expects annual net profit to increase nearly 1.4 times year-on-year.

Hubei Biocause Heilen Pharmaceutical (301211.SZ): approval of market application for gefitinib hydrochloride chemical raw material drug.

Palantir (PLTR.US) FY25 Q4 earnings call: Remaining contract value grew 105% year-on-year to reach $11.2 billion.

RECOMMEND

Multiple A‑Share Companies Update Hong Kong IPO Progress Since Start Of Year
30/01/2026

Mainland Pharmaceutical Companies Rush To Hong Kong, Over 10 Firms Queue For IPO
30/01/2026

2026 Hong Kong Market Faces Unlocking Peak: HKD 1.6 Trillion In Restricted Shares To Be Released, How Will The Market Respond?
30/01/2026


